Digest Network Come funziona
Network
/
Società
Ab
Non verificato

Abcuro, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

11 comunicati stampa

Guarda tutti i comunicati
26/03/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
24/02/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Abcuro Announces Topline Results from the MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
08/12/2025
Industria
Eventi
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Abcuro Presents Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Eventi
Industria
Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
09/06/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
11/03/2025
Industria
Eventi
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
12/02/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
11/11/2024
Eventi
Oncologia
Salute
Scienza
Medicina - Varie
Biotecnologia
Abcuro Announces Participation in Upcoming Investor Conferences
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
29/08/2024
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Eventi
Web e Social Network
Abcuro Announces Participation in Upcoming Investor Conferences
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0
31/07/2024
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Abcuro Appoints Sarah Boyce to its Board of Directors
Fonte
Abcuro, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0